Scientists at National University of Singapore and Agency for Science Technology & Research Bioprocessing Technology Institute have identified MAPK-interacting kinase (MNK) inhibitors, particularly MNK1 and MNK2 inhibitors reported to be useful for the treatment of triple-negative breast cancer (TNBC) metastatic to the brain.